Close



Feb 14, 2024 08:30AM
Nov 2, 2021 04:05PM
Sep 20, 2021 11:30AM
Sep 20, 2021 11:30AM
Sep 17, 2021 04:24PM
Sep 17, 2021 04:23PM
Aug 5, 2021 04:05PM Exelixis Announces Second Quarter 2021 Financial Results and Provides Corporate Update
Aug 5, 2021 08:01AM
Aug 5, 2021 08:00AM
Apr 29, 2021 06:59AM
Jan 22, 2021 01:10PM
Jan 10, 2021 04:00PM
Nov 5, 2020 04:05PM
Nov 5, 2020 06:59AM Bristol Myers Squibb Reports Third Quarter 2020 Financial Results
Oct 19, 2020 07:00AM
Oct 19, 2020 06:59AM
Dec 5, 2018 01:33AM
Nov 15, 2018 01:32AM
Nov 1, 2018 04:05PM
Oct 22, 2018 06:50AM
Oct 22, 2018 06:45AM Exelixis Announces Results from the Dose-Escalation Stage of the Phase 1b COSMIC-021 Study of Cabozantinib in Combination with Atezolizumab in Previously Untreated Advanced Renal Cell Carcinoma
Oct 22, 2018 06:17AM
Oct 20, 2018 08:45AM
Oct 8, 2018 06:05PM
Oct 8, 2018 08:05AM
Oct 8, 2018 08:00AM
Sep 21, 2018 05:54AM
Sep 21, 2018 01:32AM Exelixis’ Partner Ipsen Announces Positive CHMP Opinion for CABOMETYX® (cabozantinib) Tablets for Previously Treated Hepatocellular Carcinoma
Sep 7, 2018 08:15AM
Sep 7, 2018 08:00AM
Aug 1, 2018 04:05PM
Jul 5, 2018 06:05AM
Jul 4, 2018 05:00PM
Jun 4, 2018 06:47AM
Jun 3, 2018 09:00AM Exelixis Announces Results from Sub-Group Analyses of the Phase 3 Pivotal CELESTIAL Trial of Cabozantinib for Advanced Hepatocellular Carcinoma Presented at ASCO 2018
May 29, 2018 04:11PM
May 29, 2018 04:05PM
Feb 26, 2018 04:05PM
Dec 19, 2017 02:59PM
Dec 19, 2017 02:54PM
Nov 1, 2017 04:05PM
Oct 16, 2017 10:41AM UPDATE: Exelixis (EXEL) PT Raised to $33 at Needham & Company
Oct 16, 2017 09:32AM
Oct 16, 2017 07:00AM
Oct 16, 2017 06:59AM
May 12, 2016 07:53AM
Apr 20, 2016 12:10PM
Apr 20, 2016 12:06PM
Apr 4, 2016 09:58AM UPDATE: Stifel Upgrades Exelixis (EXEL) to Buy
Apr 4, 2016 09:27AM

12,336 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All